ATRA – Atara Biotherapeutics, Inc.
ATRA — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
6.51
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.13
EPS Last/This Y
-4.06
EPS This/Next Y
0.82
Price
4.59
Target Price
5
Analyst Recom
3
Performance Q
-73.91
Upside
724.2%
Beta
-0.32
Ticker: ATRA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | ATRA | 5.44 | N/A | N/A | 0 |
| 2026-03-02 | ATRA | 4.91 | N/A | N/A | 0 |
| 2026-03-03 | ATRA | 5.38 | N/A | N/A | 0 |
| 2026-03-04 | ATRA | 5.33 | N/A | N/A | 0 |
| 2026-03-05 | ATRA | 5.02 | N/A | N/A | 0 |
| 2026-03-06 | ATRA | 5.12 | N/A | N/A | 0 |
| 2026-03-09 | ATRA | 6.64 | N/A | N/A | 0 |
| 2026-03-10 | ATRA | 6.31 | N/A | N/A | 0 |
| 2026-03-11 | ATRA | 6.13 | N/A | N/A | 0 |
| 2026-03-12 | ATRA | 6.9 | N/A | N/A | 0 |
| 2026-03-13 | ATRA | 6.9 | N/A | N/A | 0 |
| 2026-03-17 | ATRA | 5.22 | N/A | N/A | 0 |
| 2026-03-18 | ATRA | 4.93 | N/A | N/A | 0 |
| 2026-03-19 | ATRA | 5.07 | N/A | N/A | 0 |
| 2026-03-20 | ATRA | 4.86 | N/A | N/A | 0 |
| 2026-03-23 | ATRA | 4.82 | N/A | N/A | 0 |
| 2026-03-24 | ATRA | 4.97 | N/A | N/A | 0 |
| 2026-03-25 | ATRA | 4.96 | N/A | N/A | 0 |
| 2026-03-26 | ATRA | 4.7 | N/A | N/A | 0 |
| 2026-03-27 | ATRA | 4.67 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | ATRA | 5.39 | 95.0 | - | 1.29 |
| 2026-03-02 | ATRA | 4.93 | 95.0 | - | 1.29 |
| 2026-03-03 | ATRA | 5.40 | 95.0 | - | 1.29 |
| 2026-03-04 | ATRA | 5.32 | 95.0 | - | 1.29 |
| 2026-03-05 | ATRA | 5.03 | 95.0 | - | 1.29 |
| 2026-03-06 | ATRA | 5.15 | 95.0 | - | 1.29 |
| 2026-03-09 | ATRA | 6.89 | 95.0 | - | 1.29 |
| 2026-03-10 | ATRA | 6.28 | 95.0 | - | 1.29 |
| 2026-03-11 | ATRA | 6.11 | 95.0 | - | 1.29 |
| 2026-03-12 | ATRA | 6.90 | 95.0 | - | 1.29 |
| 2026-03-13 | ATRA | 6.49 | 95.0 | - | 1.29 |
| 2026-03-17 | ATRA | 5.23 | 95.0 | - | 1.29 |
| 2026-03-18 | ATRA | 5.01 | 95.0 | - | 1.29 |
| 2026-03-19 | ATRA | 5.11 | 95.0 | - | 1.29 |
| 2026-03-20 | ATRA | 4.93 | -112.9 | - | -1.45 |
| 2026-03-23 | ATRA | 4.87 | -112.9 | - | -1.45 |
| 2026-03-24 | ATRA | 4.97 | -112.9 | - | -1.45 |
| 2026-03-25 | ATRA | 5.00 | -112.9 | - | -1.45 |
| 2026-03-26 | ATRA | 4.71 | -112.9 | - | -1.45 |
| 2026-03-27 | ATRA | 4.59 | -112.9 | - | -1.45 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | ATRA | -2.80 | 2.54 | 4.92 |
| 2026-03-02 | ATRA | -2.80 | 2.61 | 4.92 |
| 2026-03-03 | ATRA | -2.80 | 2.61 | 4.92 |
| 2026-03-04 | ATRA | -2.96 | 2.61 | 4.92 |
| 2026-03-05 | ATRA | -2.96 | 2.61 | 4.92 |
| 2026-03-06 | ATRA | -2.96 | 2.61 | 4.92 |
| 2026-03-09 | ATRA | -2.96 | 2.61 | 4.92 |
| 2026-03-10 | ATRA | -2.96 | 2.61 | 4.92 |
| 2026-03-11 | ATRA | -2.96 | 2.61 | 7.78 |
| 2026-03-12 | ATRA | -2.96 | 2.61 | 7.78 |
| 2026-03-13 | ATRA | -2.96 | 2.61 | 7.78 |
| 2026-03-17 | ATRA | -2.96 | 2.61 | 7.78 |
| 2026-03-18 | ATRA | -2.96 | 2.61 | 7.78 |
| 2026-03-19 | ATRA | -2.62 | 2.61 | 6.87 |
| 2026-03-20 | ATRA | -2.62 | 2.61 | 6.87 |
| 2026-03-23 | ATRA | -2.62 | 2.24 | 6.87 |
| 2026-03-24 | ATRA | -2.62 | 2.24 | 6.87 |
| 2026-03-25 | ATRA | -2.62 | 2.24 | 6.51 |
| 2026-03-26 | ATRA | -2.62 | 2.24 | 6.51 |
| 2026-03-27 | ATRA | -2.62 | 2.24 | 6.51 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.25
Avg. EPS Est. Current Quarter
-0.45
Avg. EPS Est. Next Quarter
-0.38
Insider Transactions
-2.62
Institutional Transactions
2.24
Beta
-0.32
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
48
Growth Score
33
Sentiment Score
3
Actual DrawDown %
99.1
Max Drawdown 5-Year %
-99.2
Target Price
5
P/E
1.57
Forward P/E
PEG
P/S
0.31
P/B
P/Free Cash Flow
EPS
2.91
Average EPS Est. Cur. Y
-1.45
EPS Next Y. (Est.)
-0.63
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
27.07
Relative Volume
0.11
Return on Equity vs Sector %
-112.2
Return on Equity vs Industry %
-96
EPS 1 7Days Diff
-1.2
EPS 1 30Days Diff
-1.9
EBIT Estimation
◆
ATRA
Healthcare
$4.59
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
39.7
Range 1M
1.5%
Sup Dist
0.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-126.7%
EPS NY
-13%
52W%
4.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+8.9% upside
Upside
+8.9%
Quality
48
Atara Biotherapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 14
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
ATRA
Latest News
—
Caricamento notizie per ATRA…
stock quote shares ATRA – Atara Biotherapeutics, Inc. Stock Price stock today
news today ATRA – Atara Biotherapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ATRA – Atara Biotherapeutics, Inc. yahoo finance google finance
stock history ATRA – Atara Biotherapeutics, Inc. invest stock market
stock prices ATRA premarket after hours
ticker ATRA fair value insiders trading